ES2170857T3 - Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato. - Google Patents

Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.

Info

Publication number
ES2170857T3
ES2170857T3 ES96916266T ES96916266T ES2170857T3 ES 2170857 T3 ES2170857 T3 ES 2170857T3 ES 96916266 T ES96916266 T ES 96916266T ES 96916266 T ES96916266 T ES 96916266T ES 2170857 T3 ES2170857 T3 ES 2170857T3
Authority
ES
Spain
Prior art keywords
trihydrate
methanosulfonate
hydroxi
phenylpiperidin
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916266T
Other languages
English (en)
Spanish (es)
Inventor
Marta M Andino
Terry G Sinay
Eugene F Fiese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2170857T3 publication Critical patent/ES2170857T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES96916266T 1995-08-11 1996-06-20 Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato. Expired - Lifetime ES2170857T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
ES2170857T3 true ES2170857T3 (es) 2002-08-16

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916266T Expired - Lifetime ES2170857T3 (es) 1995-08-11 1996-06-20 Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.

Country Status (41)

Country Link
US (1) US6008233A (enExample)
EP (1) EP0843661B1 (enExample)
JP (1) JP3099072B2 (enExample)
KR (1) KR100291882B1 (enExample)
CN (2) CN1615861A (enExample)
AP (1) AP755A (enExample)
AR (1) AR004676A1 (enExample)
AT (1) ATE215072T1 (enExample)
AU (1) AU710984B2 (enExample)
BG (1) BG63678B1 (enExample)
BR (1) BR9610766A (enExample)
CA (1) CA2228752C (enExample)
CO (1) CO4750830A1 (enExample)
CZ (1) CZ296236B6 (enExample)
DE (1) DE69620191T2 (enExample)
DK (1) DK0843661T3 (enExample)
DZ (1) DZ2083A1 (enExample)
ES (1) ES2170857T3 (enExample)
GT (1) GT199600051A (enExample)
HR (1) HRP960372B1 (enExample)
HU (1) HUP9802862A3 (enExample)
IL (1) IL122649A (enExample)
IS (1) IS1945B (enExample)
MA (1) MA23957A1 (enExample)
NO (1) NO310458B1 (enExample)
NZ (1) NZ309134A (enExample)
OA (1) OA10664A (enExample)
PE (1) PE4898A1 (enExample)
PL (1) PL185603B1 (enExample)
PT (1) PT843661E (enExample)
RO (1) RO120134B1 (enExample)
RS (1) RS49521B (enExample)
RU (1) RU2140910C1 (enExample)
SA (1) SA96170171B1 (enExample)
SK (1) SK284209B6 (enExample)
TN (1) TNSN96104A1 (enExample)
TR (1) TR199800208T1 (enExample)
TW (1) TW495502B (enExample)
UA (1) UA59341C2 (enExample)
WO (1) WO1997007098A1 (enExample)
ZA (1) ZA966760B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
TR199800208T1 (enExample) * 1995-08-11 1998-05-21 Pfizer Inc.
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
MXPA03001472A (es) 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
MXPA04003541A (es) * 2001-10-19 2004-07-22 Toyama Chemical Co Ltd Derivados de eter alquilo o sus sales.
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2305672B1 (en) 2008-06-13 2019-03-27 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9567341B2 (en) 2014-09-15 2017-02-14 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EP3197440A4 (en) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
JP6876625B2 (ja) 2015-06-01 2021-05-26 リューゲン ホールディングス (ケイマン) リミテッド Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
TR199800208T1 (enExample) * 1995-08-11 1998-05-21 Pfizer Inc.

Also Published As

Publication number Publication date
PE4898A1 (es) 1998-03-16
CZ39098A3 (cs) 1999-02-17
SA96170171B1 (ar) 2006-05-20
OA10664A (en) 2000-11-06
CA2228752C (en) 2002-12-10
YU46196A (sh) 1999-07-28
GT199600051A (es) 1997-12-26
PL325050A1 (en) 1998-07-06
IL122649A (en) 2001-08-26
NO310458B1 (no) 2001-07-09
RO120134B1 (ro) 2005-09-30
CA2228752A1 (en) 1997-02-27
EP0843661B1 (en) 2002-03-27
EP0843661A1 (en) 1998-05-27
DE69620191D1 (de) 2002-05-02
DZ2083A1 (fr) 2002-10-23
US6008233A (en) 1999-12-28
HRP960372A2 (en) 1998-04-30
RU2140910C1 (ru) 1999-11-10
CN1198739A (zh) 1998-11-11
DK0843661T3 (da) 2002-07-22
KR100291882B1 (ko) 2001-10-26
MA23957A1 (fr) 1997-04-01
BR9610766A (pt) 1999-07-13
AP9600856A0 (en) 1996-10-31
TNSN96104A1 (fr) 2005-03-15
IL122649A0 (en) 1998-08-16
AU5908496A (en) 1997-03-12
NO980574D0 (no) 1998-02-10
CN1615861A (zh) 2005-05-18
AU710984B2 (en) 1999-10-07
TR199800208T1 (enExample) 1998-05-21
BG63678B1 (bg) 2002-09-30
HRP960372B1 (en) 2003-04-30
NO980574L (no) 1998-02-10
UA59341C2 (uk) 2003-09-15
MX9801149A (es) 1998-05-31
CZ296236B6 (cs) 2006-02-15
PL185603B1 (pl) 2003-06-30
HUP9802862A3 (en) 1999-05-28
HUP9802862A2 (hu) 1999-04-28
SK16698A3 (en) 1999-06-11
KR19990036321A (ko) 1999-05-25
CO4750830A1 (es) 1999-03-31
IS4643A (is) 1997-12-30
RS49521B (sr) 2006-10-27
SK284209B6 (en) 2004-11-03
AP755A (en) 1999-08-02
TW495502B (en) 2002-07-21
PT843661E (pt) 2002-07-31
JPH10510552A (ja) 1998-10-13
IS1945B (is) 2004-08-13
DE69620191T2 (de) 2002-07-18
NZ309134A (en) 1999-09-29
WO1997007098A1 (en) 1997-02-27
ATE215072T1 (de) 2002-04-15
ZA966760B (en) 1998-02-09
AR004676A1 (es) 1999-03-10
BG102289A (en) 1998-09-30
JP3099072B2 (ja) 2000-10-16

Similar Documents

Publication Publication Date Title
ES2170857T3 (es) Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
CY1111965T1 (el) Βελτιωμενη συσκευη λεϊζερ χειρος για θεραπευτικη αγωγη του δερματος
AR004768A1 (es) Un cepillo de dientes que tiene un mango y un cabezal con cerdas.
ES2181176T3 (es) Sistema de afeitado.
ES2099686T1 (es) Composicion de aminoazucar y glicosaminoglicano para el tratamiento y reparacion de tejido conjuntivo.
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
HN1997000012A (es) Derivados de triazol utiles en terapia.
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
ES2105525T3 (es) 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
MX9300550A (es) Estructura de fibra absorbente.
ES2193155T3 (es) Taxanos que tienen la cadena lateral sustituida por furilo o tienilo.
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad
ES2163261T3 (es) Instalacion continua para el tratamiento de piezas de trabajo.
ES2174196T3 (es) Utilizacion de ceramida para el tratamiento de las uñas.
ES2146423T3 (es) Procedimiento para la preparacion de disulfuros y polisulfuros organicos en presencia de resinas de poliestireno-divinilbenceno (ps-dvb) que tienen grupos de guanidina o de amidina.
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
DE59504918D1 (de) Direktziehendes haarfärbemittel
ES2194129T3 (es) Compuestos farmaceuticos.
NO874241D0 (no) Terapeutisk aktive salter.
ES2107607T3 (es) Tiazolilpirroles que tienen una actividad fungicida.
MX9204286A (es) Agentes para el tratamiento de semillas.
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 843661

Country of ref document: ES